ALGETA
Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.
ALGETA
Social Links:
Industry:
Biotechnology Chemical Medical
Founded:
1997-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.algeta.com
Total Employee:
10001+
Status:
Closed
Contact:
+49 214 300
Email Addresses:
[email protected]
Total Funding:
108.85 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Microsoft Azure DNS Rackspace CSC Global DNS
Current Employees Featured
Founder
Stock Details
Investors List
Abingworth
Abingworth investment in Post-IPO Equity - Algeta
Advent Life Sciences
Advent Life Sciences investment in Series A - Algeta
SR One
SR One investment in Series A - Algeta
Advent Venture Partners
Advent Venture Partners investment in Series A - Algeta
NorgesInvestor
NorgesInvestor investment in Series A - Algeta
HealthCap
HealthCap investment in Series A - Algeta
Official Site Inspections
http://www.algeta.com
- Host name: 83.138.165.236
- IP address: 83.138.165.236
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
